|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.38 USD | -0.82% |
|
-0.70% | +5.81% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical | 4.28TCr | 5.2TCr | 5.36TCr | 5.74TCr | 5.81TCr | |||||
D&A | 60L | 50L | 50L | 50L | 50L | |||||
Operating Income | 3.1TCr | 3.69TCr | 3.89TCr | 4.45TCr | 4.58TCr | |||||
Veterinary Drugs | ||||||||||
Animal Health | 556.8Cr | 555Cr | 562.5Cr | 587.7Cr | 635.4Cr | |||||
D&A | 16Cr | 18Cr | 20Cr | 26Cr | 28Cr | |||||
Operating Income | 195Cr | 196.3Cr | 173.7Cr | 193.8Cr | 213.1Cr | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Unallocated Other Revenues | 38Cr | 172.8Cr | 91Cr | 89Cr | 52Cr | |||||
Operating Income | 16Cr | 116Cr | 47Cr | 49Cr | 25Cr | |||||
Other | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Operating Income | -141.4Cr | -164.2Cr | -162.5Cr | -184.3Cr | -275.8Cr | |||||
Operating Income | -163.6Cr | -208.5Cr | -204.4Cr | -239.5Cr | -279.3Cr | |||||
Operating Income | -1.17TCr | -1.3TCr | -3TCr | -1.74TCr | -1.5TCr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 2.24TCr | 2.72TCr | 2.85TCr | 3.23TCr | 3.65TCr | |||||
Total Assets | 1.18TCr | 1.29TCr | 1.39TCr | 1.47TCr | 1.5TCr | |||||
Europe, Middle East and Africa | 1.33TCr | 1.45TCr | 1.33TCr | 1.4TCr | 1.46TCr | |||||
Total Assets | 608.1Cr | 699.3Cr | 756.2Cr | 754.8Cr | 885.6Cr | |||||
Latin America | 220.6Cr | 258.2Cr | 308.6Cr | 345.9Cr | 341Cr | |||||
Total Assets | 20Cr | 22Cr | 22Cr | 13Cr | 13Cr | |||||
Asia Pacific (other than Japan and China) | 240.7Cr | 361.4Cr | 322.5Cr | 305.8Cr | 298.3Cr | |||||
Total Assets | 86Cr | 97Cr | 102.2Cr | 98Cr | 90Cr | |||||
Other | 122.1Cr | 256.8Cr | 210.4Cr | 255.9Cr | 287.8Cr | |||||
Total Assets | 40L | 50L | 40L | 4.7Cr | 5.1Cr | |||||
Japan | 272.6Cr | 362.9Cr | 316.4Cr | 328Cr | 271.1Cr | |||||
Total Assets | 16Cr | 14Cr | 13Cr | 14Cr | 14Cr | |||||
China | 437.8Cr | 519.1Cr | 680.2Cr | 549.4Cr | 193.9Cr | |||||
Total Assets | 22Cr | 21Cr | 19Cr | 20Cr | 22Cr | |||||
Asia Pacific | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- MRK Stock
- Financials Merck & Co., Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition